Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandrine Faivre

Showing results (41-50 of 139) with videos related to

Pageof 14
Sort By:
Targeted Oncology|June 5, 2012
Sunitinib in pancreatic neuroendocrine tumorsEric Raymond, Pascal Hammel, Chantal Dreyer, et al.
Hepatology (Baltimore, Md.)|September 2, 2017
Recent developments of c-Met as a therapeutic target in hepatocellular carcinomaMohamed Bouattour, Eric Raymond, Shukui Qin, et al.
Targeted Oncology|May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitorsCatherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical developmentMarie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
American Journal of Translational Research|July 31, 2014
Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesisIsmael Ghanem, Maria E Riveiro, Valerie Paradis, et al.
Annals of Surgical Oncology|May 30, 2013
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched studyLouise Barbier, David Fuks, Patrick Pessaux, et al.
Annals of Surgical Oncology|April 19, 2014
Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapyRomain Pommier, Maxime Ronot, François Cauchy, et al.
Journal of Hepatology|December 15, 2010
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinomaHélène Marijon, Safi Dokmak, Valérie Paradis, et al.
Investigational New Drugs|September 19, 2007
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumorsCatherine Delbaldo, Eric Raymond, Karina Vera, et al.
Pharmacology & Therapeutics|December 3, 2014
Targeting the TGFβ pathway for cancer therapyCindy Neuzillet, Annemilaï Tijeras-Raballand, Romain Cohen, et al.
Pageof 14

Showing results (41-50 of 139) with videos related to

Sort By:
Pageof 14
Targeted Oncology|June 5, 2012
Sunitinib in pancreatic neuroendocrine tumorsEric Raymond, Pascal Hammel, Chantal Dreyer, et al.
Hepatology (Baltimore, Md.)|September 2, 2017
Recent developments of c-Met as a therapeutic target in hepatocellular carcinomaMohamed Bouattour, Eric Raymond, Shukui Qin, et al.
Targeted Oncology|May 3, 2011
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitorsCatherine Delbaldo, Sébastien Albert, Chantal Dreyer, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 20, 2010
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical developmentMarie-Paule Sablin, Chantal Dreyer, Camelia Colichi, et al.
American Journal of Translational Research|July 31, 2014
Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesisIsmael Ghanem, Maria E Riveiro, Valerie Paradis, et al.
Annals of Surgical Oncology|May 30, 2013
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched studyLouise Barbier, David Fuks, Patrick Pessaux, et al.
Annals of Surgical Oncology|April 19, 2014
Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapyRomain Pommier, Maxime Ronot, François Cauchy, et al.
Journal of Hepatology|December 15, 2010
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinomaHélène Marijon, Safi Dokmak, Valérie Paradis, et al.
Investigational New Drugs|September 19, 2007
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumorsCatherine Delbaldo, Eric Raymond, Karina Vera, et al.
Pharmacology & Therapeutics|December 3, 2014
Targeting the TGFβ pathway for cancer therapyCindy Neuzillet, Annemilaï Tijeras-Raballand, Romain Cohen, et al.
Pageof 14